← Back to Clinical Trials
Recruiting NCT06270667

NCT06270667 Effects of Exercise Training in Survivors of Lymphoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06270667
Status Recruiting
Phase
Sponsor Norwegian School of Sport Sciences
Condition Lymphoma
Study Type INTERVENTIONAL
Enrollment 280 participants
Start Date 2024-03-20
Primary Completion 2028-09-01

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Aerobic ExerciseCombined Aerobic and Resistance Exercise

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 280 participants in total. It began in 2024-03-20 with a primary completion date of 2028-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the effects of aerobic exercise with or without addition of resistance exercise to usual care in individuals treated with anthracyclines for lymphomas and to compare exercise effects to age- and sex-matched individuals with no prior history of malignant diseases.

Eligibility Criteria

Inclusion Criteria Lymphoma participants: * Listed in relevant registers * Confirmed lymphoma diagnosis (i.e., Hodgkin lymphoma and aggressive non-Hodgkin lymphoma) * Completed treatment in the past two to five years without relapse or second cancer * Previous anthracycline treatment with or without mediastinal radiation * No severe cancer-related fatigue (per self-report) Inclusion Criteria Lymphoma participants and non-cancer reference group: * Currently not performing \>75 minutes/week of aerobic exercise * Willing and able to adhere to all study procedures. Exclusion Criteria Lymphoma participants: * Relapse since diagnosis * A history, or current presence, of another diagnosis of invasive cancer of any kind Exclusion Criteria Lymphoma participants and non-cancer reference group: * Presence of any uncontrolled- or recent cardiovascular disease * Has undergone heart surgery * Uses a pacemaker * Pregnancy * Unable to read and understand Swedish (applicable for the Swedish site only) * Unable to read and understand Norwegian (applicable for the Norwegian site) * Any physical or mental health condition restricting adherence to study protocol

Contact & Investigator

Central Contact

Tormod S. Nilsen, PhD

✉ tormodsn@nih.no

📞 95069857

Principal Investigator

Tormod S. Nilsen, PhD

PRINCIPAL INVESTIGATOR

Norwegian School of Sport Sciences

Frequently Asked Questions

Who can join the NCT06270667 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 70 Years, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06270667 currently recruiting?

Yes, NCT06270667 is actively recruiting participants. Contact the research team at tormodsn@nih.no for enrollment information.

Where is the NCT06270667 trial being conducted?

This trial is being conducted at Oslo, Norway, Uppsala, Sweden.

Who is sponsoring the NCT06270667 clinical trial?

NCT06270667 is sponsored by Norwegian School of Sport Sciences. The principal investigator is Tormod S. Nilsen, PhD at Norwegian School of Sport Sciences. The trial plans to enroll 280 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology